Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04530123




Registration number
NCT04530123
Ethics application status
Date submitted
25/08/2020
Date registered
28/08/2020
Date last updated
6/05/2024

Titles & IDs
Public title
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet
Secondary ID [1] 0 0
U1111-1253-8169
Secondary ID [2] 0 0
TAK-101-2001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Celiac Disease 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - TAK-101
Other interventions - Gluten

Experimental: Cohort 1, Group A: Placebo + Placebo + TAK-101 2 mg/kg - Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 milligram per kilogram (mg/kg) will be given 23 weeks after the second dose at approximately Week 24.

Experimental: Cohort 1, Group B: TAK-101 2 mg/kg + Placebo + TAK-101 2 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.

Experimental: Cohort 1, Group C: TAK-101 2 mg/kg + TAK-101 2 mg/kg + TAK-101 2 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.

Experimental: Cohort 2, Group D: Placebo + Placebo + TAK-101 2 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

Experimental: Cohort 2, Group E: TAK-101 4 mg/kg + Placebo + TAK-101 4 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

Experimental: Cohort 2, Group F: TAK-101 4 mg/kg + TAK-101 4 mg/kg + TAK-101 4 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

Experimental: Cohort 2, Group G: TAK-101 1 mg/kg + TAK-101 1 mg/kg + TAK-101 1 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24 (1 mg/kg may not be needed based on review of Cohort 1 data). Cohort 2 would start based on the results of Cohort 1.

Experimental: Cohort 2, Group D: Placebo + Placebo + TAK-101 1 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.

Experimental: Cohort 2, Group E: TAK-101 1 mg/kg + Placebo + TAK-101 1 mg/kg - Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.


Treatment: Drugs: Placebo
TAK-101 placebo-matching intravenous infusion

Treatment: Drugs: TAK-101
TAK 101 intravenous infusion

Other interventions: Gluten
Powder form (vital wheat gluten)
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Interferon-gamma Spot Forming Units (IFN-? SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay
Timepoint [1] 0 0
Baseline (Day 15, or Day 1 in the absence of Day 15) to Week 3 (Day 20)
Secondary outcome [1] 0 0
Percentage of Participants Experiencing at Least One Adverse Event (AE), Infusion Related Reaction (IRR), and Cytokine Release Syndrome (CRS)
Timepoint [1] 0 0
From the first IV dose up to 30 days after last IV dose (Up to Week 28)
Secondary outcome [2] 0 0
Change From Baseline in Nausea Severity as Measured by the Celiac Disease Symptom Diary (CDSD) 3-day Average Score
Timepoint [2] 0 0
Baseline and Day 1 post gluten challenge on Day 20 (Week 3) and Weeks 8, 14 and 20
Secondary outcome [3] 0 0
Change From Baseline in CDSD 3-day Peak Nausea Severity Score
Timepoint [3] 0 0
Baseline and Day 1 post gluten challenge on Day 20 (Week 3) and Weeks 8, 14 and 20
Secondary outcome [4] 0 0
Change From Baseline Before Gluten Challenge to 4 hours Post-gluten Challenge in Plasma Interleukin-2 (IL-2) on Day 15 and Weeks 8, 14, and 20
Timepoint [4] 0 0
Baseline, Day 15, Weeks 8, 14, 20
Secondary outcome [5] 0 0
Plasma Concentration of TAK-101 After Each Dose
Timepoint [5] 0 0
Predose and postdose at Weeks 0, 1 and 24
Secondary outcome [6] 0 0
Change From Baseline in Serum Concentration of Antidrug Antibody (ADAs) to TAK-101
Timepoint [6] 0 0
Predose at Weeks 0 and 1 and before gluten challenge at Weeks 2, 8, 14, 20, and 24

Eligibility
Key inclusion criteria
1. Biopsy-confirmed CeD that is well-controlled, defined as mild or with no ongoing signs
or symptoms felt to be related to active CeD and with immunoglobulin A (IgA) tissue
transglutaminase (tTG) <2 × upper limit of normal (ULN) and IgG deamidated gliadin
peptide (DGP) <3 × ULN.

Note: Participants may be retested for IgA tTG and IgG DGP to meet eligibility
criteria at the discretion of the investigator. Intermittent symptoms would not
exclude participants from participation as long as symptoms are generally well
controlled in the opinion of the investigator, and as long as symptoms are back to
baseline for 2 weeks before the run-in gluten challenge.

2. Must be attempting to maintain a gluten-free diet (GFD) for =6 months.

3. Must be HLA-DQ2 and/or HLA-DQ8 positive during screening laboratory testing.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Has received any investigational compound within 12 weeks (84 days) before signing of
the informed consent or during the current study.

2. Has received TAK-101 (TIMP-GLIA) in a previous clinical study or as a therapeutic
agent.

3. Has presence of inflammatory gastrointestinal disorders or autoimmune diseases, other
than well-controlled autoimmune thyroid disease or well-controlled type 1 diabetes
mellitus (defined as glycosylated hemoglobin <8% and no hospitalization in the last 12
months for hyper/hypoglycemia).

4. Has known or suspected refractory CeD or ulcerative jejunitis.

5. Has additional food allergies or intolerances that prevent participation in the food
challenge.

6. Is receiving ongoing systemic immunosuppressant, systemic (oral or IV) corticosteroid
treatment, or has received treatment with systemic immunosuppressants or
corticosteroids in the 12 weeks before run-in gluten challenge.

7. Has known or suspected chronic liver disease or positive for hepatitis B or C.

8. Has intolerable symptoms after the run-in gluten challenge and is unwilling to undergo
subsequent posttreatment gluten challenges.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/06/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/10/2025
Actual
Sample size
Target
108
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment hospital [2] 0 0
Emeritus Research, Sydney - Botany
Recruitment hospital [3] 0 0
Northern Beaches Clinical Research - Brookvale
Recruitment hospital [4] 0 0
St Vincent's Hospital Melbourne - Darlinghurst
Recruitment hospital [5] 0 0
Sutherland Shire Clinical Research - Miranda
Recruitment hospital [6] 0 0
AusTrials St Leonards - St Leonards
Recruitment hospital [7] 0 0
Wollongong Clinical Research - Wollongong
Recruitment hospital [8] 0 0
Griffith University Clinical Trial Unit - Gold Coast
Recruitment hospital [9] 0 0
Coastal Digestive Health - Maroochydore
Recruitment hospital [10] 0 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [11] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [12] 0 0
Emeritus Research, Melbourne - Camberwell
Recruitment hospital [13] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [14] 0 0
AusTrials Sunshine - St Albans
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
2019 - Botany
Recruitment postcode(s) [3] 0 0
2100 - Brookvale
Recruitment postcode(s) [4] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [5] 0 0
2228 - Miranda
Recruitment postcode(s) [6] 0 0
2065 - St Leonards
Recruitment postcode(s) [7] 0 0
2500 - Wollongong
Recruitment postcode(s) [8] 0 0
9726 - Gold Coast
Recruitment postcode(s) [9] 0 0
4558 - Maroochydore
Recruitment postcode(s) [10] 0 0
4101 - South Brisbane
Recruitment postcode(s) [11] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [12] 0 0
3124 - Camberwell
Recruitment postcode(s) [13] 0 0
3050 - Parkville
Recruitment postcode(s) [14] 0 0
3021 - St Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
New Mexico
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Manitoba
Country [27] 0 0
Canada
State/province [27] 0 0
Nova Scotia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Canada
State/province [29] 0 0
Quebec
Country [30] 0 0
New Zealand
State/province [30] 0 0
Auckland
Country [31] 0 0
New Zealand
State/province [31] 0 0
Havelock North
Country [32] 0 0
New Zealand
State/province [32] 0 0
Lower Hutt
Country [33] 0 0
New Zealand
State/province [33] 0 0
Palmerston North
Country [34] 0 0
New Zealand
State/province [34] 0 0
Wellington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and
immune activation in adult participants with celiac disease (CeD) on a gluten-free diet
(GFD).

Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All
participants will receive active treatment at Week 24.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04530123
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Takeda Contact
Address 0 0
Country 0 0
Phone 0 0
+1-877-825-3327
Fax 0 0
Email 0 0
medinfoUS@takeda.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04530123